Table 2

Tumor EGFr saturation studies

Acc no.	EGFr saturation status (%)
		EGFr saturation by IHC^a					Tyrosine kinase activity unbound				EGFr/C225 complex
		Pre tx	24 h post 1st tx	24 h pre 3rd tx	Pre tx	24 h post 1st tx	24 h pre 3rd tx	Pre tx	24 h post 1st tx	24 h pre 3rd tx
1	0	12	59^b	100	60	0	+^c	+++	++
2	0	76	32^b	ND	ND	ND	ND	ND	ND
3	0	53	10^b	100	0	0	ND	ND	ND
4	0	33	45	ND	ND	ND	ND	ND	ND
5	0	26	25	100	20	0	−	+++	+
7	0	76	36	100	70	60	−	++	+
8	0	39	95	ND	ND	ND	−^d	−^d	−^d
9	0	57	79	ND	ND	ND	−	+++	+
12	0	ND	ND	ND	ND	ND	−	+++	−

^a IHC, immunohistochemistry; tx, therapy; ND, not done or could not be evaluated.
^b Biopsies obtained 48 h after third dose of C225.
^c +, ++, +++, weak, moderate, and strong band of EGFr/C225 complex, respectively; −, no EGFr/C225 complex formation.
^d Tissue samples from Acc no. 8 may have undergone tumor necrosis and/or proteolysis.